Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Lundbeck Drug Linked to Improvement for Some Migraine Sufferers

April 2, 2022, 6:09 PM

H. Lundbeck A/S said its drug Vyepti was associated with greater improvement for some migraine sufferers in a clinical trial when compared with a placebo.

Vyepti was associated with larger declines in headache frequency and days of acute headache medication use in people diagnosed with both chronic migraine and medication overuse headache, the company said in a statement.

The European Commission granted marketing authorization for Vyepti for the prophylactic treatment of migraine in adults who have at least four migraine days per month, the Danish pharmaceutical company said Jan. 24.

To contact the reporter on this story:
Jim ...